Immunocore Holdings plc (NASDAQ:IMCR) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Immunocore Holdings plc (NASDAQ:IMCR) have been given a consensus rating of “Moderate Buy” by the thirteen analysts that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $63.73.

IMCR has been the subject of a number of research reports. Needham & Company LLC reiterated a “buy” rating and set a $71.00 target price on shares of Immunocore in a research report on Thursday, April 10th. Mizuho lowered their price objective on shares of Immunocore from $38.00 to $33.00 and set a “neutral” rating for the company in a research report on Monday, April 7th. HC Wainwright restated a “buy” rating and issued a $100.00 target price on shares of Immunocore in a report on Wednesday, March 12th. JPMorgan Chase & Co. lowered their price target on shares of Immunocore from $54.00 to $50.00 and set an “overweight” rating for the company in a report on Monday, April 14th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $35.00 price target on shares of Immunocore in a research report on Friday, March 7th.

Insider Transactions at Immunocore

In related news, Director Bros. Advisors Lp Baker acquired 807,338 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average price of $29.72 per share, for a total transaction of $23,994,085.36. Following the acquisition, the director now directly owns 2,144,060 shares of the company’s stock, valued at $63,721,463.20. This represents a 60.40 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 10.40% of the company’s stock.

Hedge Funds Weigh In On Immunocore

A number of institutional investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. bought a new position in Immunocore in the fourth quarter worth approximately $25,000. China Universal Asset Management Co. Ltd. grew its position in shares of Immunocore by 12.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company’s stock worth $248,000 after buying an additional 960 shares in the last quarter. NEOS Investment Management LLC increased its stake in shares of Immunocore by 10.9% during the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock valued at $330,000 after buying an additional 1,102 shares during the period. Tema Etfs LLC bought a new stake in shares of Immunocore in the fourth quarter valued at about $330,000. Finally, Virtus ETF Advisers LLC lifted its stake in Immunocore by 39.0% in the fourth quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company’s stock worth $340,000 after acquiring an additional 3,238 shares during the period. 84.50% of the stock is owned by hedge funds and other institutional investors.

Immunocore Price Performance

NASDAQ:IMCR opened at $29.41 on Tuesday. The company has a market capitalization of $1.47 billion, a P/E ratio of -30.96 and a beta of 0.75. The business’s 50-day moving average is $28.74 and its 200 day moving average is $30.36. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. Immunocore has a 12 month low of $23.15 and a 12 month high of $62.74.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.